It was demonstrated that the level of CD19 + BAFFR + B cells was elevated in MG patients, verifying the increased activation of B‐cell maturation.44 However, the outcome measures of GC and QMGS reduction were negative, also the risk of suffering AEs was the lowest. This evidence concerns the gene CD19 and myasthenia gravis.